The treatment of type 2 diabetes has evolved over the past decade, and incretin-based drugs, including dipeptidyl peptidase 4 (DPP4) inhibitors and glucagon-like peptide-1 (GLP-1)
The treatment of type 2 diabetes has evolved over the past decade, and incretin-based drugs, including dipeptidyl peptidase 4 (DPP4) inhibitors and glucagon-like peptide-1 (GLP-1)
